The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2173-2180

  Song, Lu ^a   Yang, Xinxin ^a   Ma, Yaping ^a   Wu, Na ^a   Liu, Zhenguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

6 hydroxydopamine; L DOPA; Motor fluctuation; Parkinson s disease; Striatum; The CB1 receptor agonist WIN 55, 212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN DARPP 32; ANTIPARKINSON AGENT; LEVODOPA; OXIDOPAMINE;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENZYME PHOSPHORYLATION; FEMALE; IN VIVO STUDY; MOTOR DYSFUNCTION; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR UPREGULATION; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; FEMALE; LEVODOPA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXIDOPAMINE; PARKINSON DISEASE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1;

EID: 84908519197     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S60944     Document Type: Article

References (37)

1. Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson’s disease. Curr Opin Investig Drugs. 2001;2(5):657–662
2. Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Ann Neurol. 2008;64 Suppl 2:S65–S80
3. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse. 2009;63(7):610–620
4. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130(Pt 7):1819–1833
5. Jaunarajs KL, Dupre KB, Steiniger A, et al. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport. 2009;20(14):1265–1269
6. Santini E, Valjent E, Fisone G. Parkinson’s disease: levodopa-induced dyskinesia and signal transduction. FEBS J. 2008;275(7):1392–1399
7. Fox SH, Chuang R, Brotchie JM. Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res. 2008;172:479–494
8. Pavón N, Martín AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry. 2006;59(1):64–74
9. Santini E, Valjent E, Usiello A, et al. Critical involvement of cAMP/ DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27(26):6995–7005
10. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry. 2007;62(7):800–810
11. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease. Mov Disord. 2002;17(6):1180–1187
12. Morgese MG, Cassano T, Cuomo V, Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson’s disease: role of CB(1) and TRPV1 receptors. Exp Neurol. 2007;208(1):110–119
13. Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson’s disease. Mov Disord. 2003;18(2):138–149
14. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82–85
15. Andersson M, Usiello A, Borgkvist A, et al. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci. 2005;25(37):8432–8438
16. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press; 2007
17. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994;662(1–2):69–74
18. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci. 2003;18(6):1607–1614
19. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 1994;5(18):2586–2588
20. Marin C, Jiménez A, Bonastre M, et al. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor fluctuations in Parkinsonian rats. Synapse. 2001;42(1):40–47
21. Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA. 2005. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol. 2005;192(1):184–193
22. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology. 2003; 61(6 Suppl 3):S4–S11
23. García-Arencibia M, García C, Fernández-Ruiz J. Cannabinoids and Parkinson’s disease. CNS Neurol Disord Drug Targets. 2009;8(6):432–439
24. Corbillé AG, Valjent E, Marsicano G, et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci. 2007;27(26):6937–6947
25. Lerner TN, Horne EA, Stella N, Kreitzer AC. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. J Neurosci. 2010;30(6):2160–2164
26. Pérez-Rial S, García-Gutiérrez MS, Molina JA, et al. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol Aging. 2011;32(4):631–645
27. Morissette M, Dridi M, Calon F, et al. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse. 2006;60(3):239–250
28. Johnston TH, van der Meij A, Brotchie JM, Fox SH. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson’s disease. Mov Disord. 2010; 25(10):1379–1390
29. Ouattara B, Hoyer D, Grégoire L, et al. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience. 2010;167(4):1160–1167
30. Cao X, Liang L, Hadcock JR, et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated rhesus monkeys. J Pharmacol Exp Ther. 2007;323(1): 318–326
31. Greengard P. The neurobiology of slow synaptic transmission. Science. 2001;294(5544):1024–1030
32. da Cruz e Silva EF, Fox CA, Ouimet CC, Gustafson E, Watson SJ, Greengard P. Differential expression of protein phosphatase 1 isoforms in mammalian brain. J Neurosci. 1995;15(5 Pt 1):3375–3389
33. Hemmings HC Jr, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984;310(5977):503–505
34. Bibb JA, Snyder GL, Nishi A, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999; 402(6762):669–671
35. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366–375
36. Bateup HS, Svenningsson P, Kuroiwa M, et al. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci. 2008;11(8):932–939
37. Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science. 1996;273(5277):959–963.